Skip to main content
Erschienen in: Pediatric Nephrology 2/2006

01.02.2006 | Original Article

Hypophosphatemic rickets: results of a long-term follow-up

verfasst von: Maria Helena Vaisbich, Vera H. Koch

Erschienen in: Pediatric Nephrology | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

This study reports the benefits and side effects of conventional treatment, phosphate and calcitriol supplementation in patients with heritable hypophosphatemic rickets and a long-term follow-up, median of 60.9 months. The group is composed of 17 patients (ten girls). Sixteen patients presented with bone pain and/or deformities, and in one patient the diagnosis was radiological. All the patients had increased alkaline phosphatase, hypophosphatemia, decreased fractional phosphate tubular reabsorption (TRP) and maximum tubular phosphate reabsorption/glomerular filtration rate ratio (TPO4/GFR). Ten of 17 patients had metabolic acidosis, which was corrected only with the conventional treatment. Potassium citrate was prescribed to the patients who developed hypercalciuria. Excluding one patient with pulmonary dysfunction, the remaining 16 patients were divided into two groups according to the age at treatment onset (T0): group I (GI) ≥4 years (n =9) and GII <4 years (n =7). GI and GII had similar follow-up periods and treatment protocols. Seven out of nine GI patients underwent orthopedic surgery, in contrast to none of GII. Anthropometric data results showed that within each group there is no difference in weight and stature z -score at T0 and at the end of the observation (Tf), but, when both groups are compared, GII shows higher z -score for stature at T0 (p <0.05) and at Tf (p <0.05). Nephrocalcinosis developed in three cases and correlated with hypercalciuria (p <0.001) and dose of calcitriol (p =0.03). In conclusion, higher stature z -score is associated with early treatment. A careful protocol is recommended to detect such complications as nephrocalcinosis. We suggest potassium citrate for patients with hypercalciuria to avoid calcium precipitation.
Literatur
1.
Zurück zum Zitat Tenehouse HS, Murer H (2003) Disorders of renal tubular phosphate transport. J Am Soc Nephrol 14:240–247CrossRefPubMed Tenehouse HS, Murer H (2003) Disorders of renal tubular phosphate transport. J Am Soc Nephrol 14:240–247CrossRefPubMed
2.
Zurück zum Zitat Kronenberg HM (2002) NPT2a—The key to phosphate homeostasis. N Eng J Med 347:1022–1024CrossRef Kronenberg HM (2002) NPT2a—The key to phosphate homeostasis. N Eng J Med 347:1022–1024CrossRef
3.
Zurück zum Zitat Takeda E, Yamamoto H, Nashiki K, Sato T, Arai H, Taketani Y (2004) Inorganic phosphate homeostasis and the role of dietary phosphorus. J Cell Mol Med 8:191–201PubMed Takeda E, Yamamoto H, Nashiki K, Sato T, Arai H, Taketani Y (2004) Inorganic phosphate homeostasis and the role of dietary phosphorus. J Cell Mol Med 8:191–201PubMed
4.
Zurück zum Zitat Nenet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM (2004) FGF-23 is processed by proprotein convertase but not by PHEX. Bone 35:455–462CrossRefPubMed Nenet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM (2004) FGF-23 is processed by proprotein convertase but not by PHEX. Bone 35:455–462CrossRefPubMed
5.
Zurück zum Zitat Liu S, Guo R, Simpson LG, Kiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278(39):37419–37426CrossRefPubMed Liu S, Guo R, Simpson LG, Kiao ZS, Burnham CE, Quarles LD (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278(39):37419–37426CrossRefPubMed
6.
Zurück zum Zitat White KE, Carn GC, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086CrossRefPubMed White KE, Carn GC, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086CrossRefPubMed
7.
Zurück zum Zitat Bowe AE, Finnegan R, Beur SMJ, Cho J, Levine MA, Kumar R, Schiavi SC (2001) FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284:977–981CrossRefPubMed Bowe AE, Finnegan R, Beur SMJ, Cho J, Levine MA, Kumar R, Schiavi SC (2001) FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284:977–981CrossRefPubMed
8.
Zurück zum Zitat Quarles LD (2003) FGF-23, PHEX and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285:E1–E9PubMed Quarles LD (2003) FGF-23, PHEX and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285:E1–E9PubMed
9.
Zurück zum Zitat Kruse A, Dracht U, Gopfert G (1982) Renal threshold phosphate concentration (TmPO4/GFR) Arch Dis Child 57:217–223 Kruse A, Dracht U, Gopfert G (1982) Renal threshold phosphate concentration (TmPO4/GFR) Arch Dis Child 57:217–223
10.
Zurück zum Zitat Brodehl J, Krause A, Hoyer P (1988) Assessment of maximal tubular phosphate reabsorption: Comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol 2:183–189CrossRefPubMed Brodehl J, Krause A, Hoyer P (1988) Assessment of maximal tubular phosphate reabsorption: Comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol 2:183–189CrossRefPubMed
11.
Zurück zum Zitat Patriquin H, Robitaille P (1986) Renal calcium deposition in children: sonographic demonstration of the Anderson-Carr progression. AJR Am J Roentgenol 146:1253–1256PubMed Patriquin H, Robitaille P (1986) Renal calcium deposition in children: sonographic demonstration of the Anderson-Carr progression. AJR Am J Roentgenol 146:1253–1256PubMed
12.
Zurück zum Zitat Kooh SW, Binet A, Daneman A (1994) Nephrocalcinosis in X-linked hypophosphatemic rickets: its relationship to treatment, kidney function, and growth. Clin Invest Med 17:123–130PubMed Kooh SW, Binet A, Daneman A (1994) Nephrocalcinosis in X-linked hypophosphatemic rickets: its relationship to treatment, kidney function, and growth. Clin Invest Med 17:123–130PubMed
13.
Zurück zum Zitat Friedman NE, Lobaugh B, Drezner MK (1993) Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 76:839–844CrossRefPubMed Friedman NE, Lobaugh B, Drezner MK (1993) Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 76:839–844CrossRefPubMed
14.
Zurück zum Zitat Doria A, Kooh SW, Cole WG, Daneman A, Sochett E (2003) Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 88:3591–3597CrossRefPubMed Doria A, Kooh SW, Cole WG, Daneman A, Sochett E (2003) Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 88:3591–3597CrossRefPubMed
15.
Zurück zum Zitat Patzer L, van’t Hoff W, Shah V, Hallson P, Kasidas GP, Samuell C, de Bruyn R, Barrat TM, Dillon MJ (1999) Urinary supersaturation of calcium oxalate and phosphate in patients with X-linked hypophosphatemic rickets and in healthy schoolchildren. J Pediatr 135:611–617PubMed Patzer L, van’t Hoff W, Shah V, Hallson P, Kasidas GP, Samuell C, de Bruyn R, Barrat TM, Dillon MJ (1999) Urinary supersaturation of calcium oxalate and phosphate in patients with X-linked hypophosphatemic rickets and in healthy schoolchildren. J Pediatr 135:611–617PubMed
16.
Zurück zum Zitat Reusz GS, Latta K, Hoyer PF, Byrd DJ, Ehrich JH, Brodehl J (1990) Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated rickets. Lancet 335:1240–1243CrossRefPubMed Reusz GS, Latta K, Hoyer PF, Byrd DJ, Ehrich JH, Brodehl J (1990) Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated rickets. Lancet 335:1240–1243CrossRefPubMed
17.
Zurück zum Zitat Schonaue E, Kruse K, Bohles HJ, Sewell AC (1992) More evidence for hyperoxaluria in phosphate-treated X-linked familial hypophosphatemic rickets. Eur J Pediatr 151:390CrossRef Schonaue E, Kruse K, Bohles HJ, Sewell AC (1992) More evidence for hyperoxaluria in phosphate-treated X-linked familial hypophosphatemic rickets. Eur J Pediatr 151:390CrossRef
18.
Zurück zum Zitat Reusz GS, Hoyer PF, Lucas M, Krohn HP, Ehrich JHH, Brodehl J (1990) X-Linked hypophosphatemic: treatment, height gain, and nephrocalcinosis. Arch Dis Child 65:1125–1128PubMed Reusz GS, Hoyer PF, Lucas M, Krohn HP, Ehrich JHH, Brodehl J (1990) X-Linked hypophosphatemic: treatment, height gain, and nephrocalcinosis. Arch Dis Child 65:1125–1128PubMed
19.
Zurück zum Zitat Alon U, Donaldson DL, Hellerstein S, Warady BA, Harris DJ (1992) Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouse. J Pediatr 120:899–905PubMed Alon U, Donaldson DL, Hellerstein S, Warady BA, Harris DJ (1992) Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouse. J Pediatr 120:899–905PubMed
20.
Zurück zum Zitat Goodyer PR, Kronick JB, Jequier S, Reade TM, Scriver CR (1987) Nephrocalcinosis and its relationship to treatment of hereditary rickets. J Pediatr 111:700–704PubMed Goodyer PR, Kronick JB, Jequier S, Reade TM, Scriver CR (1987) Nephrocalcinosis and its relationship to treatment of hereditary rickets. J Pediatr 111:700–704PubMed
21.
Zurück zum Zitat Verge CF, Lam A, Simpson JM, Cowell CT, Hoeard NJ, Silink M (1991) Effects of therapy in X-linked hypophosphatemic rickets. N Eng J Med 325:1843–1848 Verge CF, Lam A, Simpson JM, Cowell CT, Hoeard NJ, Silink M (1991) Effects of therapy in X-linked hypophosphatemic rickets. N Eng J Med 325:1843–1848
22.
Zurück zum Zitat Seikaly M, Browne R, Baum M (1996) Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia. Pediatrics 97:91–93PubMed Seikaly M, Browne R, Baum M (1996) Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia. Pediatrics 97:91–93PubMed
23.
Zurück zum Zitat Minari M, Castellani A, Garella S (1984) Renal tubular acidosis associated with vitamin D-resistant rickets. Miner Electrolyte Metab 10:371–374PubMed Minari M, Castellani A, Garella S (1984) Renal tubular acidosis associated with vitamin D-resistant rickets. Miner Electrolyte Metab 10:371–374PubMed
24.
Zurück zum Zitat Saggese G, Baroncelli GI, Bertelloni S, Perri G (1995) Long-term growth hormone treatment in children with renal hypophosphatemic rickets: Effects on growth, mineral metabolism, and bone density. J Pediatr 127:395–402PubMed Saggese G, Baroncelli GI, Bertelloni S, Perri G (1995) Long-term growth hormone treatment in children with renal hypophosphatemic rickets: Effects on growth, mineral metabolism, and bone density. J Pediatr 127:395–402PubMed
25.
Zurück zum Zitat Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G (2001) Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 138:236–243CrossRefPubMed Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G (2001) Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 138:236–243CrossRefPubMed
26.
Zurück zum Zitat Reusz GS, Miltenyi G, Stubnya G, Szabo A, Horvath C, Byrd DJ, Peter F, Tulassay T (1997) X-linked hyperphosphatemia: effects of treatment with recombinant human growth hormone. Pediatr Nephrol 11:573–577CrossRefPubMed Reusz GS, Miltenyi G, Stubnya G, Szabo A, Horvath C, Byrd DJ, Peter F, Tulassay T (1997) X-linked hyperphosphatemia: effects of treatment with recombinant human growth hormone. Pediatr Nephrol 11:573–577CrossRefPubMed
27.
Zurück zum Zitat Haffner D, Wuhl E, Blum WF, Schaefer F, Mehls O (1995) Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphatemia. Eur J Pediatr 154:610–613PubMed Haffner D, Wuhl E, Blum WF, Schaefer F, Mehls O (1995) Disproportionate growth following long-term growth hormone treatment in short children with X-linked hypophosphatemia. Eur J Pediatr 154:610–613PubMed
28.
Zurück zum Zitat Nissel R, Wuhl E, Mehls O (2004) Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 113:e593–596CrossRefPubMed Nissel R, Wuhl E, Mehls O (2004) Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 113:e593–596CrossRefPubMed
29.
Zurück zum Zitat Scott A, Rivkees AS, El-Hajj-Fuleihan G, Brown EM, Crawford JD (1992) Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 75:1514–1518CrossRefPubMed Scott A, Rivkees AS, El-Hajj-Fuleihan G, Brown EM, Crawford JD (1992) Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 75:1514–1518CrossRefPubMed
30.
Zurück zum Zitat Gosnell JE, Posen S, Reeve TS, Delbridge LW (2004) Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets. Arch Surg 139:218–222CrossRefPubMed Gosnell JE, Posen S, Reeve TS, Delbridge LW (2004) Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets. Arch Surg 139:218–222CrossRefPubMed
Metadaten
Titel
Hypophosphatemic rickets: results of a long-term follow-up
verfasst von
Maria Helena Vaisbich
Vera H. Koch
Publikationsdatum
01.02.2006
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 2/2006
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-005-2077-4

Weitere Artikel der Ausgabe 2/2006

Pediatric Nephrology 2/2006 Zur Ausgabe

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.